Masthead-Image-Right-min

PAMA Reform: The Introduction of the RESULTS Act Legislation

What the new legislation could mean for labs, providers, and the future of diagnostic testing.

Continue Reading...

The End of an Era: FDA is Rescinding Long-Contested LDT Rule for Labs

Withdrawal of LDT Rule Provides Regulatory Clarity and Reimbursement Guidance for Laboratories

Continue Reading...

UnitedHealth Group's Turmoil: The Impact on Labs and Pathology Groups

Rising costs, regulatory scrutiny, and shifting payer dynamics could reshape lab and pathology practice operations and reimbursements.

Continue Reading...

Healthcare's New Law: Preparing for the “One Big Beautiful Bill” Act

The new law brings transformative changes to Medicare, Medicaid, and patient cost-sharing, requiring providers to strategically adapt revenue cycle operations.

Continue Reading...

What's Next for LDTs? A Look Beyond the Ruling

Get the key takeaways from our expert-led webinar on the LDT final rule ruling—and why labs must stay vigilant as the story unfolds.

Continue Reading...